医学
生活质量(医疗保健)
肺癌
临床试验
外科
物理疗法
内科学
护理部
作者
Runsen Jin,Zhengyuan Zhang,Yuyan Zheng,Zhenyi Niu,Shang Sun,Yuqin Cao,Yajie Zhang,Abbas E. Abbas,Toni Lerut,Jules Lin,Hecheng Li
出处
期刊:Chest
[Elsevier]
日期:2023-06-01
卷期号:163 (6): 1576-1588
被引量:5
标识
DOI:10.1016/j.chest.2022.12.037
摘要
Robot-assisted lobectomy (RAL) is increasingly used as an alternative to video-assisted lobectomy (VAL) for resectable non-small cell lung cancer (NSCLC). However, there is little evidence of any difference in postoperative health-related quality of life (HRQoL) between these two approaches.Is RAL superior to VAL in improving quality of life in patients with resectable NSCLC?We performed a single-center, open-label randomized clinical trial from May 2017 to May 2020 with 320 enrolled patients undergoing RAL or VAL for resectable NSCLC (RVlob trial; NCT03134534). Postoperative pain was evaluated by visual analog score or numeric rating score on postoperative day 1 and at weeks 4, 24, and 48. The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30), EORTC Quality of Life Questionnaire in Lung Cancer (QLQ-LC13), and the European Quality of Life 5 Dimensions (EQ-5D) questionnaire were also administered at weeks 4, 24, and 48 after surgery.One hundred and fifty-seven patients underwent RAL and 163 underwent VAL. The mean pain score of patients after RAL was significantly lower at week 4 (2.097 ± 0.111 vs 2.431 ± 0.108; P = .032). QLQ-C30 and QLQ-LC13 summary scores (P > .05) were similar for both RAL and VAL during the first 48 weeks of follow-up. HRQoL scores assessed with the EQ-5D questionnaire were also comparable between the two groups (P > .05) during the whole study period.Both RAL and VAL showed satisfactory and comparable HRQoL and postoperative pain up to 48 weeks after surgery, despite some minor statistical differences at week 4.ClinicalTrials.gov; No.: NCT03134534; URL: www.gov.
科研通智能强力驱动
Strongly Powered by AbleSci AI